A phase II trial of gemcitabine and weekly high-dose 5-fluorouracil in a 48-hour continuous-infusion schedule in patients with advanced pancreatic carcinoma. A study of the Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD).

Joan Maurel Santasusana,José Luis García López,Juan José Bretón García,Ana Isabel León Carbonero,Javier Gallego Plazas,Pedro Sánchez Rovira,Carlos Fernández-Martos,Ma Carmen Galán Guzmán,Jesús Florián Jericó,F.J. Delgado,Javier Casinello Espinosa,Marta Llanos Muñoz,E. Aguilar,Javier Sastre Valera,Ignacio García Ribas,Alfredo Carrato Mena

A phase II trial of gemcitabine and weekly high-dose 5-fluorouracil in a 48-hour continuous-infusion schedule in patients with advanced pancreatic carcinoma. A study of the Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD).

2005

Joan Maurel Santasusana
José Luis García López
Juan José Bretón García
Ana Isabel León Carbonero
Javier Gallego Plazas
Pedro Sánchez Rovira
Carlos Fernández-Martos
Ma Carmen Galán Guzmán
Jesús Florián Jericó
F.J. Delgado
Javier Casinello Espinosa
Marta Llanos Muñoz
E. Aguilar
Javier Sastre Valera
Ignacio García Ribas
Alfredo Carrato Mena

Aim A multi-centred, open-labelled, phase II study containing 46 patients was conducted to evaluate the clinical benefit of gemcitabine (1,400 mg/m2) combined with 5-FU (3 g/m2) in a 48 h continuous infusion (CI).

Keywords:

General surgery
Fluorouracil
Progression-free survival
Carcinoma
Gemcitabine
Medicine
continuous infusion
Oncology
in patient
cooperative group
Phases of clinical research
pancreatic carcinoma
tumour therapy
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations